Kaneda H, Tachihara M, Toi Y, Kuyama S, et al. Phase II study of ramucirumab plus erlotinib for treatment-naive patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion). Lung Cancer 2026;217:109432.
PMID: 42096800